ArcticZymes Technologies Successfully Upscales SAN HQ Enzyme Production
Tromsø, Norway, 26[th] March 2021 – ArcticZymes Technologies ASA (OSE: AZT) announces it has successfully scaled-up the manufacturing of its SAN HQ enzymeArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme offers gene therapy and vaccine customers a more cost effective and technically superior solution for the removal of contaminating DNA during the manufacturing process of therapeutic viruses. The Company entered the therapeutic segment with its SAN portfolio in 2016. Since then, it has rapidly grown its customer base and subsequent sales. In 2020 the segment